You are here
Interpreting clinical trial data for daily clinical practice: How to work with what we have available in first-line mCRPC
Professor Gero Kramer, AKH Medical University, Vienna, comments on decision making in real life patients with metastatic castration resistant prostate cancer (mCRPC). We need studies to decide when to start treatment - Is it better to treat earlier and will this change the natural history of patients with mCRPC? Head- to-head-comparison-trials are necessary to determine which agent, e.g. abiraterone or enzalutamide, and in which sequence should be used. In addition comorbidities and comedications as well as the patient’s preference with the regard to the prospected adverse effects have to be considered.